Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Drug Profile

Tc 99m tilmanocept - Navidea Biopharmaceuticals

Alternative Names: Lymphoseek; NEO3-09; Tc 99m-diethylenetriamine pentaacetic acid mannosyl dextran; Tc 99m-DTPA-mannosyl dextran; Technetium Tc 99m tilmanocept; Tilmanocept

Latest Information Update: 31 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California, San Diego
  • Developer Maimonides Medical Center; National Cancer Institute (USA); National Institute of Health Clinical Center; Navidea Biopharmaceuticals; Norgine; University of California, San Diego
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Breast cancer; Head and neck cancer; Malignant melanoma; Solid tumours; Squamous cell cancer
  • Phase II Cardiovascular disorders; Cervical cancer; Kaposi's sarcoma
  • Phase I/II Rheumatoid arthritis
  • Phase I Endometrial cancer; Liver metastases; Non-alcoholic steatohepatitis
  • Clinical Phase Unknown Crohn's disease
  • No development reported Colorectal cancer

Most Recent Events

  • 08 Oct 2018 Navidea Biopharmaceuticals withdraws a phase I trial in Rheumatoid arthritis (Diagnosis) prior to enrolment as trial was combined with another ongoing trial (NCT03241446)
  • 05 Sep 2018 Launched for Breast cancer (Diagnosis) in Spain (Intradermal)
  • 05 Sep 2018 Launched for Malignant melanoma (Diagnosis) in Spain (Intradermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top